Epigral Q1 FY26 earnings call: Revenue & Margins
Q1 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹607Cr
- −6.8% YoY
- −3.3% QoQ
- Net profit
- ₹160Cr
- +86% YoY
- +83.9% QoQ
- Margin
- 27%
- 0 pp YoY
- −1 pp QoQ
Guidance rank: #31 of 70 in Chemicals & Petrochemicals
See the sector's top 10 — free with your mobile number.
The short version
Epigral aims for consistent growth driven by expansion and diversification into multiproducts serving various industries. Epigral targets consistent growth driven by expansion and diversification into multiproduct segments catering to various industries.
From Epigral Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Epigral aims for consistent growth driven by expansion and diversification into multiproducts serving various industries.
- Revenue contribution from derivatives and specialty business is targeted to increase from 50% in Q1 FY26 to 70% by FY28.
- The recently commissioned Chlorotoluene value chain is expected to generate sizable revenue by the end of FY26, with commercial order clarity by Q4 FY26.
- Expansion projects including doubling capacities of CPVC resin and Epichlorohydrin (ECH) are on schedule, expected to boost volumes and sales in FY27 and FY28.
- New product evaluations and projects on existing and newly acquired land at Dahej aim to add growth beyond 2028, focusing on import substitution chemicals with expected double-digit CAGR (~12-13%) over 10 years.
2 more points from Epigral Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Epigral Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Epigral is currently executing capex projects including doubling the capacity of CPVC resin and Epichlorohydrin plants.
- A 19.8 MW wind-solar hybrid power plant expansion is underway, expected to add to a total of 38 MW hybrid capacity.
- Ongoing expansion capex for FY '26 is around INR 450 crores, with roughly INR 120 crores already spent; a similar capex range (~INR 400-450 crores) is expected for FY '27.
- Company is evaluating a project within the existing complex to optimize infrastructure; this will be the last at this site.
2 more points from Epigral Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Epigral Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Pipeline customers for chlorine include Meghmani company and other nearby companies supplied via pipeline; chlorine is partly sold through pipeline and partly to the general market.
- Trial orders for Chlorotoluenes are ongoing, commercial scale ramp-up anticipated by end of Q3 FY '26.
- The company expects consistent growth in its multiproduct pipeline aligned with expansion and diversification strategies.
Epigral Ltd — Quarterly revenue & net profit
Epigral Ltd Q1 FY26 results — key figures
| ₹ Cr | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 607 | 651 | -6.8% | 628 | -3.3% |
| Operating profit (EBITDA) | 163 | 176 | -7.4% | 173 | -5.8% |
| Operating margin | 27% | 27% | 0 pp | 28% | -1 pp |
| Profit before tax | 107 | 131 | -18.3% | 131 | -18.3% |
| Net profit (PAT) | 160 | 86 | +86% | 87 | +83.9% |
| EPS (₹) | 37.18 | 20.70 | +79.6% | 20.08 | +85.2% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹746 Cr, net profit ₹64 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Epigral's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Balaji Amines (Q1 FY26)
Q1FY26 consolidated revenue from operations: ₹367 crore, up 2% quarter-on-quarter from ₹361 crore in Q4FY25, but down 7% year-on-year from ₹393 crore in Q1FY25…
- Linde India (Q1 FY26)
Net Revenue for FY ended Mar’25 was INR 24,854 million, down 10.2% (–2,833 million) YoY from INR 27,687 million. Key concall takeaways from Linde India Ltd's…
- Vidhi Specialty (Q1 FY26)
87.9 Crores . Key concall takeaways from Vidhi Specialty Food Ingredients Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- Chemcon Speciality Chemicals (Q1 FY26)
Q1 FY26 revenue from operations: ₹53.5 Cr, up 18% YoY from ₹45.5 Cr in Q1 FY25 (Page 7 & 6). Key concall takeaways from Chemcon Speciality Chemicals Ltd's Q1…
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Epigral Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Epigral Ltd Q1 FY26 results?
Epigral aims for consistent growth driven by expansion and diversification into multiproducts serving various industries. Epigral targets consistent growth driven by expansion and diversification into multiproduct segments catering to various industries.
What is Epigral Ltd share price analysis?
Epigral Ltd currently shows a neutral. The stock trades at a P/E of 17.8 with a market cap of ₹4,828 Cr. Investors should review the full earnings analysis for detailed insights.
Is Epigral Ltd planning capital expenditure?
Epigral is currently executing capex projects including doubling the capacity of CPVC resin and Epichlorohydrin plants.
Keep Epigral Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
